GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome

Neurogastroenterology and Motility

Volumn 20, Issue 6, 2008, Pages 649-659

  Hellstrom P M ^a   Naslund E ^b   Edholm, T ^a   Schmidt, P T ^a   Kristensen, J ^a   Theodorsson, E ^c   Holst, J J ^d   Efendic, S ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b DANDERYD HOSPITAL   (Sweden)

^c Neurochemistry Unit   (Sweden)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antro duodeno jejnunal motility; Glucagon like peptides; Peptide hormones; Proglucagon

Indexed keywords

GASTROINTESTINAL HORMONE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; SODIUM CHLORIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; FEMALE; HUMAN; HUMAN TISSUE; IRRITABLE COLON; JEJUNUM; MALE; MANOMETRY; MOTOR ACTIVITY; NAUSEA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH ANTRUM; STOMACH MOTILITY;

ADOLESCENT; ADULT; DUODENUM; FEMALE; GASTROINTESTINAL MOTILITY; GLUCAGON-LIKE PEPTIDE 1; HUMANS; IRRITABLE BOWEL SYNDROME; JEJUNUM; MALE; MIDDLE AGED; MYOELECTRIC COMPLEX, MIGRATING; PYLORIC ANTRUM;

EID: 43549094932     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2007.01079.x     Document Type: Article

References (52)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987 2 : 1300 4.
2. Elliott RM, Morgan LM, Tredger JA, Deacon S, Wright J, Marks V. Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in reponse to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. J Endocrinol 1993 138 : 159 66.
3. Edwards CM, Todd JF, Mahmoudi M et al. Glucagon-like peptide 1has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999 48 : 86 93.
4. Schjoldager BT, Mortensen PE, Christiansen J, Ørskov C, Holst JJ. GLP-1 (glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans. Dig Dis Sci 1989 34 : 703 8.
5. Schirra J, Kuwert P, Wank U et al. Differential effects of subcutaneous GLP-1 on gastric emptying, gastroduodenal motility, and pancreatic function in man. Proc Assoc Am Physicians 1997 109 : 84 97.
6. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest 1998 102 : 764 74.
7. Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellström PM. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 1998 43 : 2284 90.
8. Schirra J, Leicht P, Hildebrand P et al. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus. J Endocrinol 1998 156 : 177 86.
9. Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interdigestive state and with duodenal lipid perfusion in humans. Gut 2000 46 : 622 31.
10. Schirra J, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1 (7-36)amide on motility and sensation of the proximal stomach in humans. Gut 2002 50 : 341 8.
11. Deacon CF, Pridal L, Klarskov L, Olesen M, Holst JJ. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol 1996 271 : E458 64.
12. Imeryuz N, Yegen BC, Bozkurt A, Coskun T, Villanueva-Penacarrillo ML, Ulusoy NB. Glucagon-like peptide 1 inhibits gastric emptying via vagal afferent-mediated central mechanism. Am J Physiol 1997 273 : G920 7.
13. Gulpinar MA, Bozkurt A, Coskun T, Ulusoy NB, Yegen BC. Glucagon-like peptide (GLP-1) is involved in the central modulation of fecal output in rats. Am J Physiol 2000 278 : G924 9.
14. Näslund E, Skogar S, Efendic S, Hellström PM. Glucagon-like peptide-1 analogue LY315902: effect on intestinal motility and release of insulin and somatostatin. Regul Pept 2002 106 : 89 95.
15. Wettergren A, Wøjdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998 19 : 877 82.
16. Wettergren A, Wøjdemann M, Holst JJ. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998 275 : G984 92.
17. Tolessa T, Näslund E, Hellström PM. The inhibitory mechanism of GLP-1, but not glucagon, on fasted gut motility is dependent on the L-arginine/nitric oxide pathway. Regul Pept 2001 98 : 33 40.
18. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987 92 : 1885 93.
19. Kellow JE, Gill RC, Wingate DL. Prolonged ambulant recordings of small bowel motility demonstrate abnormalities in the irritable bowel syndrome. Gastroenterology 1990 98 : 1208 18.
20. Lind CD. Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 1991 20 : 279 95.
21. Kellow JE, Langeluddecke PM, Eckersley GM, Jones MP, Tennant CC. Effects of acute psychologic stress on small-intestinal motility in health and the irritable bowel syndrome. Scand J Gastroenterol 1992 27 : 53 8.
22. Schmidt T, Hackelsberger N, Widmer R, Meisel C, Pfeiffer A, Kaess H. Ambulatory 24-hour jejunal motility in diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol 1996 31 : 581 9.
23. Evans PR, Bennett EJ, Bak YT, Tennant CC, Kellow JE. Jejunal sensorimotor dysfunction in irritable bowel syndrome: clinical and psychosocial features. Gastroenterology 1996 110 : 393 404.
24. Small PK, Loudon MA, Hau CM, Noor N, Campbell FC. Large-scale ambulatory study of postprandial jejunal motility in irritable bowel syndrome. Scand J Gastroenterol 1997 32 : 39 47.
25. Fehmann HC, Hering BJ, Wolf MJ et al. The effects of glucagon-like petide-I (GLP-I) on homrone secretion from isolated human pancreatic islets. Pancreas 1995 11 : 196 200.
26. Holst JJ, Ørskov C, Nielsen OV, Schwartz TW. Truncated glucagon-like petide I, an insulin -releasing hormone from the distal gut. FEBS Lett 1987 211 : 169 74.
27. Mojsov S, Weir GC, Habener JF. Insulinotropin: glucagon-like peptide-I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 1987 79 : 616 9.
28. Ørskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 (proglucagon-(78-107)amide) on endocrine secretion from pig pancreas, antrum, and non-antral stomach. Endocrinology 1988 123 : 2009 13.
29. Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Müller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999 45 (Suppl. 2 1143 7.
30. Vantrappen G, Janssens J, Hellemans J, Ghoos Y. The interdigestive motor complex of normal subjects and patients with bacterial overgrowth of the small intestine. J Clin Invest 1977 59 : 1158 66.
31. Schmidt PT, Ljung T, Hartmann B, Hare KJ, Holst JJ, Hellström PM. Tissue levels and postprandial secretion of the intestinal growth factor, GLP-2, in inflammatory bowel disease: comparison with PYY. Eur J Gastroenterol Hepatol 2005 17 : 207 12.
32. Nilsson BI, Svenberg T, Tollström T, Hellström PM, Samuelson K, Schnell PO. Relationship between interdigestive gallbladder emptying, plasma motilin and migrating motor complex in man. Acta Physiol Scand 1990 139 : 55 61.
33. Lördal M, Theodorsson E, Hellström PM. Tachykinins influence interdigestive rhythm and contractile strength of human small intestine. Dig Dis Sci 1997 42 : 1940 9.
34. Näslund E, Bogefors J, Skogar S et al. GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 1999 277 : R910 6.
35. Gutniak M, Juntti-Berggren L, Hellström PM, Guenifi A, Holst JJ, Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996 19 : 857 63.
36. Gutniak M, Svartberg J, Hellström PM, Holst J, Adner N, Ahren B. Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 2001 250 : 81 7.
37. Mortensen K, Christensen LL, Holst JJ, Ørskov C. GLP-1 and GIP are co-localized in a subset of endocrine cells in the small intestine. Regul Pept 2003 114 : 189 96.
38. Giralt M, Vergara P. Sympathetic pathways mediate GLP-1 actions in the gastrointestinal tract of the rat. Regul Pept 1998 74 : 19 25.
39. Giralt M, Vergara P. Glucagon-like peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat. Dig Dis Sci 1999 44 : 322 9.
40. Schirra J, Houck P, Wank U, Arnold R, Göke B, Katschinski M. Effects of glucagon-like peptide-1(7-36)amide on antro-pyloro-duodenal motility in the interigestive state and with duodenal lipid perfusion in humans. Gut 2006 46 : 622 31.
41. Näslund E, Bogefors J, Grybäck P et al. GLP-1 inhibits gastric emptying of water but does not influence plasma vasopressin. Scand J Gastroenterol 2001 36 : 156 62.
42. Ritchie J. Pain from distention of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973 14 : 125 32.
43. Cook I, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987 93 : 727 33.
44. Trimble KC, Farouk R, Pryde A, Douglas S, Heading R. Heightened visceral sensation in functional GI disease is not site specific. Evidence for a generalized disorder of gut sensitivity. Dig Dis Sci 1995 40 : 1607 13.
45. Fukudo S, Nomura T, Hongo M. Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome. Gut 1998 42 : 845 9.
46. Accarino AM, Azpiroz F, Malagelada JR. Selective dysfunction of mechanosensitive intestinal afferents in irritable bowel syndrome. Gastroenterology 1995 108 : 927 31.
47. Serra J, Salvioli B, Azpiroz F, Malagelada JR. Lipid-induced intestinal gas retention in irritable bowel syndrome. Gastroenterology 2002 123 : 700 6.
48. Törnblom H, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002 123 : 1972 9.
49. Hoelzl R, Erasmus L, Kratzmair M. Peripheral transduction mechanisms in visceral pain perception of irrtable bowel patients. In : Singer M, Goebell H, eds. Nerves and the Gastrointestinal Tract, Falk Symposium 50. Lancaster : Kluwer Academic, 1989 : 797 8.
50. Lembo T, Munakata J, Mertz H et al. Evidence for the hypersensitivity of lumbar planchnic afferents in irritable bowel syndrome. Gastroenterology 1994 107 : 1686 96.
51. Whitehead W, Holtkotter B, Enck P et al. Tolerance to rectosigmoid distention in irritable bowel syndrome. Gastroenterology 1990 98 : 1187 92.
52. Fielding J. The diagnostic sensitivity of physical signs in the irritable bowel syndrome. Ir Med J 1981 74 : 143 4.